PCN32 ECONOMIC EVALUATION OF SUNITINIB, SORAFENIB, BEVACIZUMAB/ INTERFERON ALPHA AND TEMSIROLIMUS IN FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ISRAEL
May 1, 2009, 00:00
10.1016/S1098-3015(10)73269-1
https://www.valueinhealthjournal.com/article/S1098-3015(10)73269-1/fulltext
Title :
PCN32 ECONOMIC EVALUATION OF SUNITINIB, SORAFENIB, BEVACIZUMAB/ INTERFERON ALPHA AND TEMSIROLIMUS IN FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ISRAEL
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)73269-1&doi=10.1016/S1098-3015(10)73269-1
First page :
Section Title :
Open access? :
No
Section Order :
694